Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi‐institutional cohort
International Journal of Urology · 2023
DOI: 10.1111/iju.15214 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Urology, 2023. Verfasst von Shinya Somiya und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Ijinkai Takeda General Hospital, Kyoto, Japan. Hauptthemen laut MEDLINE: Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Kidney Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben.
Abstract (Originalsprache)
Introduction
This study aimed to identify preoperative risk factors and create a risk classification for intravesical recurrence of upper urinary tract urothelial carcinoma only after laparoscopic radical nephroureterectomy in a multi‐institutional cohort.
Methods
We retrospectively analyzed 283 patients who had undergone laparoscopic radical nephroureterectomy for nonmetastatic upper tract urothelial cancer between March 2002 and March 2020. The cumulative incidence of intravesical recurrence for 224 patients without previous or concomitant bladder cancer was examined using multivariate Fine‐Gray competing risks proportional hazards models. A risk stratification model was created to predict subsequent patient outcomes based on the results.
Results
The median follow‐up duration was 33.3 months, and 71 (31.7%) patients experienced intravesical recurrence. The estimated cumulative incidence of intravesical recurrence at one and 5 years was 23.5% and 36.4%, respectively. In multivariate analysis, the presence of ureter tumors and multiple tumors were shown to be independently significant predictive factors for intravesical recurrence. Based on the results, we classified patients into three risk groups. The cumulative incidence rates of intravesical recurrence within 5 years after surgery were 24.4%, 42.5%, and 66.7% in the low‐, intermediate‐, and high‐risk groups, respectively.
Conclusions
We identified risk factors and created a risk classification model for intravesical recurrence of upper urinary tract urothelial carcinoma only after laparoscopic radical nephroureterectomy. Based on this model, an individualized surveillance protocol or adjuvant therapy could be provided.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Ijinkai Takeda General Hospital, Kyoto, Japan.
- Department of Urology, Hamamatsu Rosai Hospital, Hamamatsu, Japan.
- Department of Urology, Rakuwakai Otowa Hospital, Kyoto, Japan.
ORCID-Profile: Shinya Somiya, Katsuhiro Ito, Toshifumi Takahashi, Shigeki Koterazawa, Toru Kanno
Zitieren
APA
Somiya, S., Kobori, G., Ito, K., Nakagawa, H., Takahashi, T., Koterazawa, S., Takaoka, N., Haitani, T., Nagahama, K., Ito, M., Megumi, Y., Higashi, Y., Moroi, S., Akao, T., Yamada, H., & Kanno, T. (2023). Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi‐institutional cohort. International Journal of Urology. https://doi.org/10.1111/iju.15214
Vancouver
Somiya S, Kobori G, Ito K, Nakagawa H, Takahashi T, Koterazawa S, et al. Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi‐institutional cohort. International Journal of Urology. 2023. doi:10.1111/iju.15214
BibTeX
@article{Somiya2023,
author = {Somiya, Shinya and Kobori, Go and Ito, Katsuhiro and Nakagawa, Hiromichi and Takahashi, Toshifumi and Koterazawa, Shigeki and Takaoka, Naoto and Haitani, Takao and Nagahama, Kanji and Ito, Masaaki and Megumi, Yuzuru and Higashi, Yoshihito and Moroi, Seiji and Akao, Toshiya and Yamada, Hitoshi and Kanno, Toru},
title = {Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi‐institutional cohort},
journal = {International Journal of Urology},
year = {2023},
doi = {10.1111/iju.15214}
}
EUVIMED